Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
...
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- Lawrence Fong
- Registration Number
- NCT01530984
- Locations
- 🇺🇸
University of California, San Francisco, California, United States
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2022-07-11
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 36
- Registration Number
- NCT01524991
- Locations
- 🇺🇸
IU Health Goshen Hospital, Goshen, Indiana, United States
🇺🇸Tisch Cancer Institute at Mount Sinai Medical Center, New York, New York, United States
🇺🇸City of Hope: Duarte, Duarte, California, United States
RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA
- Conditions
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 22
- Registration Number
- NCT01497808
- Locations
- 🇺🇸
Abramson Cancer Center of the Universirty of Pennsylvania, Philadelphia, Pennsylvania, United States
A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2
- First Posted Date
- 2011-11-28
- Last Posted Date
- 2015-07-21
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 15
- Registration Number
- NCT01480323
- Locations
- 🇩🇪
University Hospital Tübingen, Tübingen, Germany
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 22
- Registration Number
- NCT01449279
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT01445379
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT01409174
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01409187
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-06-21
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT01377389
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease
- First Posted Date
- 2011-05-17
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Prof. Dr. med. Dirk Schadendorf
- Target Recruit Count
- 171
- Registration Number
- NCT01355120
- Locations
- 🇩🇪
Johannes Wesling Klinikum Minden, Minden, Germany
🇩🇪Ludwig-Maximilians-Universität München, München, Germany
🇩🇪Klinikum Kassel GmbH, Kassel, Hessen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.